Magle Chemoswed Holding Ab (MAGLE) Fair Value & Analysis
Healthcare · SE · Market cap 20.9M SEK (≈ $2.2M) · ISIN SE0014401014
Strengths
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 15 days ago
Fair value updated Aug 13, 2026, revised from kr 1.30 to kr 0.6600 (−49.1%) since Jul 13, 2026. Share price −32.6% over the past month.
Below-average quality, trading 45% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (23/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (kr 0.4900). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.4900 to kr 0.9900) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 0.3640 – kr 46.00 · fair‑value band kr 0.4900 – kr 0.9900 · the kr 0.3640 price screens below the kr 0.6600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Magle Chemoswed Holding Ab (MAGLE) currently trades at kr 0.3640, while our model-based Fair Value estimate is kr 0.6600, implying the stock looks roughly 81.3% undervalued today. The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Magle Chemoswed Holding Ab generated revenue of 288M SEK at a net margin of -55.6%. Revenue declined 14.5% year over year. It earns a return on equity of -33.4%. Net debt stands at 333M SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 0.4900 (bear case) to kr 0.9900 (bull case); at kr 0.3640, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -59% fair-value upside, at 81%, MAGLE screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when MAGLE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden.
Full company description
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Magle Chemoswed Holding Ab reported revenue of kr 283M in FY2025 versus kr 132M in FY2021, a compound +21.0%/yr. Reported net income was −kr 160M in FY2025.
Watch MAGLE: get an alert when its fair value changes →
Peer Group
Biotechnology · 637 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.29 | $278.78 | -49% |
| Regeneron Pharmaceuticals, Inc REGN | $814.79 | $594.40 | -27% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,594,000 KRW | 1,055,793 KRW | -34% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| BioNTech SE BNTX | $112.56 | $45.75 | -59% |
| Incyte Corporation INCY | $128.12 | $115.79 | -10% |
Compare Magle Chemoswed Holding Ab with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Magle Chemoswed Holding Ab (MAGLE) overvalued or undervalued?
What is the fair value of MAGLE?
What is the quality score of MAGLE?
What is the revenue of Magle Chemoswed Holding Ab (MAGLE)?
What is the net profit margin of MAGLE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Magle Chemoswed Holding Ab in the live analysis
One click puts Magle Chemoswed Holding Ab on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.